Afam Capital Inc. Has $4.79 Million Stake in Gilead Sciences, Inc. (GILD)
Afam Capital Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,601 shares of the biopharmaceutical company’s stock after buying an additional 3,966 shares during the period. Afam Capital Inc.’s holdings in Gilead Sciences were worth $4,785,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of GILD. Penserra Capital Management LLC grew its position in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. grew its position in Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $172,000. 76.23% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have weighed in on GILD. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Maxim Group set a $94.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Monday. Berenberg Bank reissued a “buy” rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Sunday, August 20th. Finally, Credit Suisse Group reissued a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.11.
Gilead Sciences, Inc. (GILD) opened at $76.58 on Thursday. The stock has a market cap of $99,119.69, a price-to-earnings ratio of 7.92, a P/E/G ratio of -1.27 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.75 EPS. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.72%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.
In related news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Afam Capital Inc. Has $4.79 Million Stake in Gilead Sciences, Inc. (GILD)” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/afam-capital-inc-has-4-79-million-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.